{"title":"Sexual Health Peptides","description":"\u003cp\u003eResearch-grade sexual health peptides including PT-141, Kisspeptin-10, and Melanotan MT-2. High-purity, lab-tested. For research use only.\u003c\/p\u003e","products":[{"product_id":"melanotan-mt-2-10mg","title":"Melanotan MT-2 10mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/MelanotanMT-210mg.png?v=1779543711\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eMelanotan II (MT-2) 10mg is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) designed for research and laboratory use. MT-2 is a non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R) that has been investigated in preclinical and clinical research settings for its effects on melanogenesis, sexual function, appetite regulation, and energy homeostasis. It served as the parent compound from which the more selective PT-141 (bremelanotide) was derived. Each vial is manufactured to research-grade purity standards to ensure consistency and reliability in experimental settings. Ideal for qualified researchers and institutions studying melanocortin receptor pharmacology, pigmentation biology, and neuroendocrine signalling. Store at 2–8°C. For research purposes only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredient: Melanotan II (MT-2) Chemical Name: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ Molecular Formula: C₅₀H₆₉N₁₅O₉ Molecular Weight: 1,024.18 g\/mol CAS Number: 121062-08-6 Structure: Cyclic heptapeptide α-MSH analogue Receptor Activity: Non-selective MC1R, MC3R, MC4R, MC5R agonist Purity: ≥95% (HPLC) Form: Lyophilised powder Appearance: White to off-white lyophilised powder Storage: 2–8°C (refrigerated) Shelf Life: 2 years from manufacture date Reconstitution: Sterile water or bacteriostatic saline Intended Use: Laboratory and research applications only\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store in original sealed vial at 2–8°C, protected from direct sunlight and moisture. Stable for up to 2 years when stored properly. Storage After Reconstitution: Store reconstituted solution at 2–8°C and use within 3–7 days. Discard after 24 hours at room temperature. Maintain sterile technique to prevent contamination. Avoid repeated freeze-thaw cycles. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eMelanotan II: Design and Melanocortin Receptor Pharmacology\u003c\/strong\u003e\u003cbr\u003eHadley ME, et al. (1996). \u003cem\u003eDiscovery and development of novel melanogenic drugs. Melanotan-I and -II.\u003c\/em\u003e Pharmaceutical Biotechnology, 9, 575–595. \u003ca href=\"https:\/\/doi.org\/10.1007\/978-1-4615-5833-0_29\"\u003ehttps:\/\/doi.org\/10.1007\/978-1-4615-5833-0_29\u003c\/a\u003e\u003cbr\u003eFoundational paper describing the design and synthesis of Melanotan I and II as cyclic α-MSH analogues, characterising their melanocortin receptor binding profiles and establishing the pharmacological basis for MT-2 as a potent, non-selective MC receptor agonist.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMT-2 and Melanogenesis: MC1R-Mediated Pigmentation\u003c\/strong\u003e\u003cbr\u003eDorr RT, et al. (1996). \u003cem\u003eEvaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.\u003c\/em\u003e Life Sciences, 58(20), 1777–1784. \u003ca href=\"https:\/\/doi.org\/10.1016\/0024-3205(96)00160-9\"\u003ehttps:\/\/doi.org\/10.1016\/0024-3205(96)00160-9\u003c\/a\u003e\u003cbr\u003ePhase I clinical research study evaluating MT-2’s pharmacokinetics and melanogenic activity, demonstrating dose-dependent skin pigmentation via MC1R activation and providing the key translational pharmacodynamic reference for MT-2 melanogenesis research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMT-2 and MC4R-Mediated Sexual Function\u003c\/strong\u003e\u003cbr\u003eWessells H, et al. (1998). \u003cem\u003eSynthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.\u003c\/em\u003e Journal of Urology, 160(2), 389–393. \u003ca href=\"https:\/\/doi.org\/10.1016\/S0022-5347(01)62899-X\"\u003ehttps:\/\/doi.org\/10.1016\/S0022-5347(01)62899-X\u003c\/a\u003e\u003cbr\u003eDouble-blind, placebo-controlled crossover study demonstrating MT-2’s pro-erectile activity via central MC4R activation, establishing the mechanistic basis for melanocortin agonism in sexual function research and providing the pharmacological rationale for the subsequent development of PT-141.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMT-2 and MC4R in Appetite and Energy Homeostasis\u003c\/strong\u003e\u003cbr\u003eFan W, et al. (1997). \u003cem\u003eRole of melanocortinergic neurons in feeding and the agouti obesity syndrome.\u003c\/em\u003e Nature, 385(6612), 165–168. \u003ca href=\"https:\/\/doi.org\/10.1038\/385165a0\"\u003ehttps:\/\/doi.org\/10.1038\/385165a0\u003c\/a\u003e\u003cbr\u003eLandmark study establishing MC4R as the primary hypothalamic receptor mediating melanocortin-induced anorexia and energy expenditure, providing the mechanistic context for MT-2’s appetite-suppressing effects observed in preclinical research models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMelanocortin Receptor Subtypes: Pharmacology and Distribution\u003c\/strong\u003e\u003cbr\u003eWikberg JE, et al. (2000). \u003cem\u003eNew aspects on the melanocortins and their receptors.\u003c\/em\u003e Pharmacological Research, 42(5), 393–420. \u003ca href=\"https:\/\/doi.org\/10.1006\/phrs.2000.0725\"\u003ehttps:\/\/doi.org\/10.1006\/phrs.2000.0725\u003c\/a\u003e\u003cbr\u003eComprehensive review of MC1R–MC5R receptor subtypes, tissue distribution, and signalling pathways, providing the complete receptor pharmacology framework for understanding MT-2’s broad non-selective agonist activity across multiple melanocortin receptor subtypes.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248640090455,"sku":"ML10","price":19.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/MelanotanMT-210mg.png?v=1779543711"},{"product_id":"pt141-10mg","title":"PT141 10mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/pt141-10mg_75877525-ff6d-45af-85f3-7693ae0ffcc1.png?v=1779537351\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003ePT141 is a research peptide studied for its potential effects on sexual function and arousal in both men and women. This 10mg vial is designed for laboratory and research purposes only. PT141 works through a different mechanism than traditional treatments, targeting melanocortin receptors in the brain rather than vascular pathways. Research suggests it may promote spontaneous desire and improve response regardless of psychological state. Each vial contains 10mg of lyophilized peptide powder. Intended for qualified researchers and educational use in controlled settings.\u003c\/p\u003e\n\u003cp\u003ePeptide Sequence: PT-141 (Bremelanotide analog) Molecular Weight: 1025.18 g\/mol Purity: ≥98% (HPLC) Form: Lyophilized powder Vial Size: 10mg Storage: Keep refrigerated at 2–8°C. Protect from light. Reconstitution: Reconstitute with sterile water or bacteriostatic saline as needed for research applications. Research Use Only: Not for human consumption. For laboratory and qualified research purposes only.\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C50H71N15O10 CAS Number: 189691-06-3 Amino Acid Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store lyophilized powder at 2–8°C in a refrigerator. Keep vial tightly sealed in its original container. Protect from light and moisture. Under these conditions, the peptide remains stable for up to 24 months. Storage After Reconstitution: Once reconstituted with sterile water or bacteriostatic saline, store the solution at 2–8°C. Reconstituted PT141 is stable for approximately 2–4 weeks when kept refrigerated and protected from light. For extended storage, freeze reconstituted solution at −20°C, where it remains viable for several months. Avoid repeated freeze-thaw cycles.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003ePT-141 (Bremelanotide) Origins: Derivation from Melanotan II\u003c\/strong\u003e\u003cbr\u003eHadley ME \u0026amp; Dorr RT. (2006). \u003cem\u003eMelanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.\u003c\/em\u003e Peptides, 27(4), 921–930. \u003ca href=\"https:\/\/doi.org\/10.1016\/j.peptides.2005.01.029\"\u003ehttps:\/\/doi.org\/10.1016\/j.peptides.2005.01.029\u003c\/a\u003e\u003cbr\u003eReviews the development of melanocortin peptide analogues including the derivation of PT-141 (bremelanotide) from Melanotan II, detailing the structure–activity relationships that led to its cyclic heptapeptide design and selective melanocortin receptor profile.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMelanocortin Receptor Pharmacology: MC3R and MC4R\u003c\/strong\u003e\u003cbr\u003eWikberg JE, et al. (2000). \u003cem\u003eNew aspects on the melanocortins and their receptors.\u003c\/em\u003e Pharmacological Research, 42(5), 393–420. \u003ca href=\"https:\/\/doi.org\/10.1006\/phrs.2000.0725\"\u003ehttps:\/\/doi.org\/10.1006\/phrs.2000.0725\u003c\/a\u003e\u003cbr\u003eComprehensive review of the five melanocortin receptor subtypes (MC1R–MC5R), their tissue distribution, and signalling pathways — establishing the receptor pharmacology through which PT-141 exerts its central nervous system effects via MC3R and MC4R activation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePT-141 and Central Mechanisms of Sexual Arousal\u003c\/strong\u003e\u003cbr\u003eMolinoff PB, et al. (2003). \u003cem\u003ePT-141: a melanocortin agonist for the treatment of sexual dysfunction.\u003c\/em\u003e Annals of the New York Academy of Sciences, 994, 96–102. \u003ca href=\"https:\/\/doi.org\/10.1111\/j.1749-6632.2003.tb03167.x\"\u003ehttps:\/\/doi.org\/10.1111\/j.1749-6632.2003.tb03167.x\u003c\/a\u003e\u003cbr\u003eCharacterises PT-141’s mechanism of action as a centrally acting melanocortin agonist, demonstrating that its pro-erectile and pro-arousal effects in preclinical models are mediated through hypothalamic MC4R activation rather than peripheral vascular pathways — distinguishing it mechanistically from PDE5 inhibitors.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePT-141 Phase 2 Clinical Research in Male Subjects\u003c\/strong\u003e\u003cbr\u003eDiamond LE, et al. (2004). \u003cem\u003eA double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.\u003c\/em\u003e International Journal of Impotence Research, 16(1), 51–59. \u003ca href=\"https:\/\/doi.org\/10.1038\/sj.ijir.3901139\"\u003ehttps:\/\/doi.org\/10.1038\/sj.ijir.3901139\u003c\/a\u003e\u003cbr\u003eDouble-blind, placebo-controlled Phase 2 trial evaluating intranasal PT-141 pharmacokinetics and pharmacodynamics, demonstrating significant pro-erectile activity and establishing the compound’s safety and tolerability profile in a controlled clinical research setting.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBremelanotide (PT-141) in Female Sexual Dysfunction Research\u003c\/strong\u003e\u003cbr\u003eClayton AH, et al. (2016). \u003cem\u003eBremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.\u003c\/em\u003e Women’s Health, 12(3), 325–337. \u003ca href=\"https:\/\/doi.org\/10.2217\/whe-2016-0018\"\u003ehttps:\/\/doi.org\/10.2217\/whe-2016-0018\u003c\/a\u003e\u003cbr\u003eRandomised, placebo-controlled dose-finding trial of bremelanotide (PT-141) in premenopausal women, providing key pharmacodynamic and tolerability data across dose ranges and establishing the research basis for melanocortin agonism in female sexual arousal disorder models.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248665878871,"sku":"P41","price":16.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/pt141-10mg_75877525-ff6d-45af-85f3-7693ae0ffcc1.png?v=1779537351"},{"product_id":"kisspeptin-10-5mg","title":"Kisspeptin-10 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/KISSPEPTIN5MGGLOSS.png?v=1779534656\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eKisspeptin-10 is a neuropeptide recognized for its role in regulating reproductive and metabolic pathways. This 5mg formulation is designed for research and educational purposes, offering a pure, standardized compound for scientific investigation. Kisspeptin-10 functions as a potent signaling molecule that interacts with GPR54 receptors, making it valuable for studying neuroendocrine mechanisms. Researchers utilize this peptide to explore its effects on hormone secretion, appetite regulation, and energy homeostasis. Each vial contains precisely measured Kisspeptin-10, suitable for in vitro studies and controlled research applications. The product is supplied in lyophilized form for stability and ease of reconstitution. Ideal for academic institutions, pharmaceutical research, and advanced study protocols seeking to understand peptide signaling in biological systems.\u003c\/p\u003e\n\u003cp\u003eKisspeptin-10 5mg — Research Grade Peptide Purity: ≥95% (HPLC) Molecular Weight: 1,391.7 Da Sequence: Tyr-Asn-Pro-Gly-Leu-Arg-Phe-Gly-Pro Form: Lyophilized powder Vial Size: 5mg per vial Storage: 2–8°C or -20°C for extended stability Reconstitution: Sterile water or PBS recommended Applications: In vitro research, neuroendocrine studies, receptor binding assays Receptor Target: GPR54 (KISS1R) Certificate of Analysis: Included with each order Shelf Life: 24 months from manufacture (when stored correctly)\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C₅₀H₇₉N₁₅O₁₂ This formula represents the complete elemental composition of the Kisspeptin-10 decapeptide, derived from its amino acid sequence (Tyr-Asn-Pro-Gly-Leu-Arg-Phe-Gly-Pro). The molecular weight of 1,391.7 Da corresponds directly to this formula, confirming structural identity for research applications.\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution Lyophilized Kisspeptin-10 vials should be stored at 2–8°C (refrigerator) for routine use or -20°C (freezer) for extended stability and long-term preservation. Keep vials in their original packaging, protected from light and moisture. Under these conditions, the product maintains ≥95% purity for 24 months from the date of manufacture. Avoid repeated freeze-thaw cycles, as these can compromise peptide integrity. Storage After Reconstitution Once reconstituted in sterile water or PBS, Kisspeptin-10 solutions are significantly less stable than the lyophilized form. Store reconstituted solutions at 2–8°C and use within 2–4 weeks for optimal activity. For longer-term storage of reconstituted peptide, -20°C is recommended, though activity may gradually decline. Prepare only the quantity needed for immediate use to minimize degradation. Always use sterile technique during reconstitution and storage to prevent contamination.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e1. Kotani M, et al. (2001)\u003c\/strong\u003e\u003cbr\u003eThe metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54.\u003cbr\u003e\u003cem\u003eJournal of Biological Chemistry\u003c\/em\u003e, 276(37), 34631–34636.\u003cbr\u003eDOI: \u003ca href=\"https:\/\/doi.org\/10.1074\/jbc.M104847200\"\u003e10.1074\/jbc.M104847200\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e2. Seminara SB, et al. (2003)\u003c\/strong\u003e\u003cbr\u003eThe GPR54 gene as a regulator of puberty.\u003cbr\u003e\u003cem\u003eNew England Journal of Medicine\u003c\/em\u003e, 349(17), 1614–1627.\u003cbr\u003eDOI: \u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa035322\"\u003e10.1056\/NEJMoa035322\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e3. Dhillo WS, et al. (2005)\u003c\/strong\u003e\u003cbr\u003eKisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.\u003cbr\u003e\u003cem\u003eJournal of Clinical Endocrinology \u0026amp; Metabolism\u003c\/em\u003e, 90(12), 6609–6615.\u003cbr\u003eDOI: \u003ca href=\"https:\/\/doi.org\/10.1210\/jc.2005-1468\"\u003e10.1210\/jc.2005-1468\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e4. Navarro VM, et al. (2005)\u003c\/strong\u003e\u003cbr\u003ePersistent impairment of hypothalamic KiSS-1 system after exposures to estrogenic compounds at critical periods of brain sex differentiation.\u003cbr\u003e\u003cem\u003eEndocrinology\u003c\/em\u003e, 146(5), 2356–2363.\u003cbr\u003eDOI: \u003ca href=\"https:\/\/doi.org\/10.1210\/en.2004-1331\"\u003e10.1210\/en.2004-1331\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e5. Jayasena CN, et al. (2011)\u003c\/strong\u003e\u003cbr\u003eKisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.\u003cbr\u003e\u003cem\u003eJournal of Clinical Investigation\u003c\/em\u003e, 124(8), 3667–3677.\u003cbr\u003eDOI: \u003ca href=\"https:\/\/doi.org\/10.1172\/JCI68730\"\u003e10.1172\/JCI68730\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e6. Pinilla L, et al. (2012)\u003c\/strong\u003e\u003cbr\u003eKisspeptins and reproduction: physiological roles and regulatory mechanisms.\u003cbr\u003e\u003cem\u003ePhysiological Reviews\u003c\/em\u003e, 92(3), 1235–1316.\u003cbr\u003eDOI: \u003ca href=\"https:\/\/doi.org\/10.1152\/physrev.00037.2010\"\u003e10.1152\/physrev.00037.2010\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cem\u003eFor research use only. Not for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248691306839,"sku":"KS5","price":19.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/KISSPEPTIN5MGGLOSS.png?v=1779534656"}],"url":"https:\/\/www.mutantpeptides.com\/collections\/sexual-health-peptides.oembed","provider":"Mutant Peptides Ltd","version":"1.0","type":"link"}